Travere Therapeutics, Inc.
NASDAQTravere Therapeutics heads into early June with a familiar tension: analysts raising targets and the Street broadly bullish on FILSPARI's rare-disease story, while a 15.6% short interest and a cluster of insider selling in May signal that not everyone is leaning the same direction. The positioning picture is one of genuine divergence. Short interest has climbed roughly 10% over the…
Snapshot as of 23 Jun 2026
Travere Therapeutics heads into early June with a familiar tension: analysts raising targets and the Street broadly bullish on FILSPARI's rare-disease story, while a 15.6% short interest and a cluster of insider…
Travere Therapeutics arrives at the close of this week carrying two competing stories: a Q1 earnings beat that pulled the entire sell-side to raise its targets, and a cluster of insider sales from the same management…
Travere Therapeutics heads into its May 7 earnings with a striking divergence: short sellers have been exiting while analysts race to raise targets, leaving the stock 47% higher than a month ago with defensive options…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TVTX — free to start on ORTEX.
Sign up for free →Open TVTX on ORTEX